ANG Lifesciences acquires formulation manufacturing plants from Ind-Swift

ANG Lifesciences India said that it has acquired two formulation manufacturing facilities in Baddi, Himachal Pradesh from Ind-Swift Limited for INR 60 crores.

The acquired plants are now operating as Unit 5 and Unit 6 of ANG Lifesciences India and will help scale the company’s manufacturing capacity to handle the increasing demand from the domestic and international markets.

The company said that the acquisition aligns with its long-term objective to become a complete healthcare solution provider that offers a broad-based basket of pharmaceutical formulation products for a differentiated and comprehensive profile in pharmaceutical markets.

One of the acquired units, which spans over an area of 2.85 acres, manufactures tablets, liquid injection ampoules, liquid injection vials, and dry syrups. It is expected to have a sales turnover of INR 350-500 crores.

The other formulation manufacturing facility in Baddi manufactures soft gelatin capsules, lotions, and ointments. ANG Lifesciences India expects to see a sales turnover of INR 100-200 crores from the plant.